Latest content
-
Read
Top 8 targeted protein degradation conferences of 2023 at a glance
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
-
ReadHow early discovery and development teams use Dynamic Light Scattering to de-risk downstream biologics development
As a discovery or early development scientist, you’re tasked with identifying the most promising biologics candidates. Your hard work during early development enables straightforward and efficient...
-
Read8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
-
Read
Top 8 biologics conferences of 2023 at a glance
Use this downloadable list of 2023 biologics conferences to select which one to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
-
4:51WatchFour integrated technologies for Biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics
-
1:39WatchHow Coriolis Pharma screens a vast chemical library for stabilizing excipients
Discover how Coriolis Pharma found the best excipients to stabilize their monoclonal antibodies for long-term storage. You’ll learn about the importance of expanding the chemical space for excipients
-
1:31WatchHow Janssen optimizes the stability of a therapeutic mAb
Discover how Janssen improved the stability of a promising prostate cancer targeting mAb. You’ll learn why it is important to optimize stability measurements of a therapeutic mAb.
-
2:34WatchHow 2bind identifies the best buffer for a vaccine antigen target with Prometheus Panta
Discover how 2bind applied multi-parameter characterization from a single experiment to find the optimal buffer for a vaccine antigen target.
-
Read8 biologics conferences you won’t want to miss in 2023
When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.
- Contact Specialist
-
ReadLearn the pros and cons of these 3 methods to serotype your AAV gene therapy vectors
-
37:25WatchPut your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
-
ReadNanoTemper announces Monolith X with breakthrough Spectral Shift technology, enabling affinity measurements where other methods fail
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
-
2:20WatchIntroducing Monolith X - the only way to get binding affinities in solution using very minimal sample
-
Read
The only way to get binding affinities in solution using very minimal sample
-
Read
Select the best biologics candidates with high-quality, multi-parameter stability characterization
-
Read5 benefits of optimizing your formulation buffer to get your AAV therapeutic approved
As a gene therapy scientist, you face an abundance of challenges when working to build an effective AAV therapeutic. Many steps of the development workflow have yet to be standardized and the...
-
Read
Characterize your PROTAC hook effect with flexible and in-solution affinity measurements for results you can trust
-
14:07WatchSerotyping: why, when, and how to assess your AAV therapeutic to get it approved
When you develop an AAV therapeutic, you need to assess many key parameters, or Critical Quality Attributes (CQAs), in order to track progress and, ultimately, get your therapeutic approved. As part
-
Read
Rely on Dianthus to overcome roadblocks in your PROTAC characterizations
-
ReadNanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer
MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...
-
Loading more...
